Sanofi $SNY Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. grew its position in Sanofi (NASDAQ:SNY) by 133.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,413,640 shares of the company’s stock after acquiring an additional 807,767 shares during the quarter. Victory Capital Management Inc.’s holdings in Sanofi were worth $66,681,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. AR Asset Management Inc. increased its stake in Sanofi by 40.0% during the third quarter. AR Asset Management Inc. now owns 14,000 shares of the company’s stock valued at $661,000 after purchasing an additional 4,000 shares during the last quarter. Aviso Financial Inc. boosted its holdings in shares of Sanofi by 4.7% in the 3rd quarter. Aviso Financial Inc. now owns 47,144 shares of the company’s stock valued at $2,225,000 after buying an additional 2,109 shares during the period. American Century Companies Inc. grew its position in shares of Sanofi by 19.4% during the 3rd quarter. American Century Companies Inc. now owns 2,338,969 shares of the company’s stock valued at $110,399,000 after buying an additional 379,784 shares during the last quarter. Harvest Portfolios Group Inc. raised its stake in Sanofi by 7.5% during the third quarter. Harvest Portfolios Group Inc. now owns 37,400 shares of the company’s stock worth $1,765,000 after acquiring an additional 2,600 shares during the period. Finally, AlphaCore Capital LLC lifted its holdings in Sanofi by 441.9% in the third quarter. AlphaCore Capital LLC now owns 15,234 shares of the company’s stock worth $719,000 after acquiring an additional 12,423 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent research reports. Guggenheim lowered Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. TD Cowen reiterated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Citigroup assumed coverage on shares of Sanofi in a report on Tuesday, January 27th. They set a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Five investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Sanofi has a consensus rating of “Hold” and a consensus price target of $62.67.

Sanofi Stock Performance

SNY opened at $45.00 on Friday. The business has a 50 day moving average price of $47.39 and a two-hundred day moving average price of $48.51. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. The company has a market capitalization of $109.76 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.